Logo

Eli Lilly Stops P-III (EMPA-KIDNEY) Trial of Jardiance Due to Positive Efficacy in Patients with CKD

Share this

Eli Lilly Stops P-III (EMPA-KIDNEY) Trial of Jardiance Due to Positive Efficacy in Patients with CKD

Shots:

  • The IDMC recommended that the (EMPA-KIDNEY) trial be stopped early, following a formal interim assessment, that met prespecified criteria for positive efficacy
  • The P-III (EMPA-KIDNEY) study evaluates the efficacy and safety of Jardiance in 6,600+ adults with CKD. The trial is being conducted, analyzed and reported by the MRC Population Health Research Unit at the University of Oxford with 1EPs as a composite of kidney disease progression or CV death
  • The 2EPs include CV death or hospitalization for HF, all-cause hospitalization and all-cause mortality. The company anticipated the results of the study in H2’22

Ref: PR Newswire | Image: Lilly

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions